Acadia Pharmaceuticals
| Formerly | Receptor Technologies |
|---|---|
| Company type | Public |
| |
| Industry | |
| Founded | 1993 |
| Headquarters | San Diego, California, U.S. |
Key people | Stephen R. Davis (CEO) |
| Products | Pimavanserin |
| Revenue | US$339.08 million (2019) |
| US$−246.55 million (2019) | |
| US$−235.26 million (2019) | |
| Total assets | US$783.18 million (2019) |
| Total equity | US$699.14 million (2019) |
Number of employees | 570 (June 30, 2020) |
| Website | acadia |
| Footnotes / references | |
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.